Focus Partners Wealth
TEVA icon

Focus Partners Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Focus Partners Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Buy
35,560
+1,164
+3% +$38.8K ﹤0.01% 1572
2026
Q1 		$1.04M Sell
34,396
-561,933
-94% -$18.1M ﹤0.01% 1606
2025
Q4 		$12.3M Sell
596,329
-19,408
-3% -$478K 0.01% 635
2025
Q3 		$12.4M Buy
615,737
+562,563
+1,058% +$9.88M 0.02% 505
2025
Q2 		$891K Buy
53,174
+13,100
+33% +$211K ﹤0.01% 1191
2025
Q1 		$616K Buy
40,074
+1,739
+5% +$31.1K ﹤0.01% 1248
2024
Q4 		$845K Buy
38,335
+3,071
+9% +$55.9K ﹤0.01% 1114
2024
Q3 		$635K Buy
+35,264
New +$617K ﹤0.01% 1076

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Focus Partners Wealth's TEVA Position: Q2 2026 in Review

Focus Partners Wealth increased its Teva Pharmaceuticals (TEVA) stake by 3.4% in Q2 2026, buying an estimated $38.8K and bringing the position to 35,560 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1572.

Focus Partners Wealth first reported a position in TEVA in Q3 2024 and has held it in 8 quarters since. The position peaked at $12.4M in Q3 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Focus Partners Wealth held 35,560 shares of Teva Pharmaceuticals worth $1.2M as of Q2 2026.
  • Focus Partners Wealth bought 1,164 Teva Pharmaceuticals shares in Q2 2026, an estimated $38.8K.
  • Teva Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1572 holding.
  • Focus Partners Wealth first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Focus Partners Wealth's Teva Pharmaceuticals position peaked at $12.4M in Q3 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.